Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.95 USD | +0.75% | -7.76% | -25.00% |
28/05 | Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia | CI |
23/05 | Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.00% | 285.04Cr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr | |
+77.64% | 887.31Cr |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call